BMJ

OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ...

Background Cadherin-11 is expressed on fibroblasts in joints of RA patients and augments local fibroblast–mediated inflammation, pannus formation and tissue invasion (1). RG6125 is a novel humanized ...
BMJ

AB1069 URIC ACID LEVELS IN RELATION TO FASTING BLOOD GLUCOSE AND HbA1c

2 Farhat Hached Hospital, Endocrinology and Diabetes Department, Sousse, Tunisia Background Hyperuricemia is reported to be a risk factor for the development of type 2 diabetes (T2D) and prediabetes.
BMJ

OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ...

1 Alpine Immune Sciences, Translational Sciences, Seattle, United States of America 2 Alpine Immune Sciences Inc, Immunology, Seattle, United States of America 3 Alpine Immune Sciences Inc, Clinical ...
BMJ

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
BMJ

Cure as a treatment target in rheumatoid arthritis and systemic sclerosis—achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration

The past 25 years have witnessed a remarkable revolution in outcomes for patients living with rheumatoid arthritis (RA). Historically, uncontrolled joint inflammation was commonplace leading to ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

OP0196 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study

Background Immune Checkpoint Inhibitors (ICI) have revolutionised the management of several cancers, enhancing the anti-tumoral immune response. However they are responsible for many Immune Related ...
BMJ

Relationship between serum urate and changes in dual-energy CT monosodium urate crystal volume over 1 year in people with gout: an individual participant data analysis

Objectives The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. This study aimed to systematically examine the ...
BMJ

OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

Background Interleukin-23 (IL-23), a key regulator of multiple effector cytokines, has been implicated in the pathogenesis of psoriatic lesions, synovitis, enthesitis, and bone erosion. Risankizumab ...
BMJ

Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’

Correspondence to Xiaoqing Peng, Department of Obstetrics and Gynaecology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China; pengxiaoqing{at}ahmu.edu.cn We read with ...
BMJ

Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis

Department of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, Shanghai, China Correspondence to Dr Yang Zaixing and Professor Renqian Zhong, Department of Laboratory ...
BMJ

Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, ...